Eikon Therapeutics, Inc.
EIKN Nasdaq
SEC CIK 1861123
Follow Eikon Therapeutics
Weekly email: filings, results
Net income
−$86.1M
−21% vs same quarter last year
EPS, diluted
−$1.59
+93.4% vs same quarter last year
Operating cash flow
−$69.2M
−16.2% vs same quarter last year
Operating income
−$90.6M
−21.1% vs same quarter last year
Source: SEC XBRL filings · latest filing